Advertisement

Current Ophthalmology Reports

, Volume 7, Issue 1, pp 59–65 | Cite as

Myopic Choroidal Neovascularization: Diagnosis and Treatment Update

  • Mariana R. ThorellEmail author
  • Raquel Goldhardt
Retina (R Goldhardt, Section Editor)
  • 15 Downloads
Part of the following topical collections:
  1. Topical Collection on Retina

Abstract

Purpose of Review

To review the diagnosis and treatment of myopic choroidal neovascularization. Imaging tests currently available and the advantages of each modality for detecting choroidal neovascularization signs are discussed. The management options and the outcomes of different treatment options are also reviewed.

Recent Findings

Anti-vascular endothelial growth factor has become the preferable choice of treatment in myopic choroidal neovascularization cases with improved results. The benefits of a single injection followed by PRN dosing were supported by randomized clinical trials.

Summary

Choroidal neovascularization is a common vision threatening complication in patients with pathologic myopia. Most of the patients with this condition are younger than 50 years, and the major concern is to have vision preserved later in life. The investigation of myopic choroidal neovascularization imposes additional tests to be performed in most cases. Anti-vascular endothelial growth therapy has demonstrated superior efficacy over other treatment modalities. However, further studies are required for investigation of the risk factors for recurrences and the long-term treatment strategies.

Keywords

Pathological myopia Degenerative myopia Choroidal neovascularization Optical coherence tomography Vascular endothelial growth factors 

Notes

Acknowledgements

The editors thank Dr. André Freitas for lending his expertise and reviewing this manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Financial Support

Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S, NIH Center Core Grant P30EY014801, and Research to Prevent Blindness Unrestricted Grant.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Neelam K, Cheung CMG, Ohno-Matsui K, Lai TYY, Wong TY. Choroidal neovascularization in pathological myopia. Prog. Retin. Eye Res. Elsevier Ltd; 2012;31:495–525. Available from:  https://doi.org/10.1016/j.preteyeres.2012.04.001.
  2. 2.
    •• Tan NW, Ohno-Matsui K, Koh HJ, Nagai Y, Pedros M, Freitas RL, et al. Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the radiance study. Retina. 2018;38(11):2228-382238. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221407. The study confirmed the long-term effectiveness of Ranibizumab over an additional 36 months of follow up in a cohort of East-Asian patients from the RADIANCE study.
  3. 3.
    Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology. 2002;109:704–11. https://www.aaojournal.org/article/S0161-6420(01)01024-7/fulltext
  4. 4.
    Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91:1573–81 Available from: http://www.ncbi.nlm.nih.gov/pubmed/6084222.CrossRefGoogle Scholar
  5. 5.
    Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology. 1983;90:923–6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/6195574.CrossRefGoogle Scholar
  6. 6.
    Liu HH, Xu L, Wang YX, Wang S, You QS, Jonas JB. Prevalence and progression of myopic retinopathy in Chinese adults: The Beijing eye study. Ophthalmolog. Elsevier Inc.; 2010;117:1763–1768. Available from:  https://doi.org/10.1016/j.ophtha.2010.01.020.
  7. 7.
    Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Kojima A, Hayashi W, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology. 2010;117:1595–611 1611.e1-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20207005.CrossRefGoogle Scholar
  8. 8.
    Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am. J. Ophthalmol. 2014;157:9–25.e12 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002939413005473.CrossRefGoogle Scholar
  9. 9.
    Ng DSC, Lai TYY, Cheung CMG, Ohno-Matsui K. Anti–vascular endothelial growth factor therapy for myopic choroidal neovascularization. Asia-Pacific J. Ophthalmol. 2017:1741–6 Available from: http://www.apjo.org/Apjo/pdf/id/551.html.
  10. 10.
    Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241–4 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8764794.CrossRefGoogle Scholar
  11. 11.
    Wong TY, Foster PJ, Hee J, Ng TP, Tielsch JM, Chew SJ, et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest. Ophthalmol. Vis. Sci. 2000;41:2486–94 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10937558.Google Scholar
  12. 12.
    Tano Y. Pathologic myopia: where are we now? Am. J. Ophthalmol. 2002;134:645–60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12429239.CrossRefGoogle Scholar
  13. 13.
    Willis JR, Vitale S, Morse L, Parke DW, Rich WL, Lum F, et al. The prevalence of myopic choroidal neovascularization in the United States: analysis of the IRIS(®) data registry and NHANES. Ophthalmology. 2016;123:1771–82 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27342789.CrossRefGoogle Scholar
  14. 14.
    Chan W, Ohji M, Lai TYY, Liu DTL, Tano Y, Lam DSC. Choroidal neovascularisation in pathological myopia - an update in management. Br J Ophthalmol. 2005;89(11):1522–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772951.
  15. 15.
    Miller DG, Singerman LJ. Natural history of choroidal neovascularization in high myopia. Curr. Opin. Ophthalmol. 2001;12:222–4 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11389351.CrossRefGoogle Scholar
  16. 16.
    Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, Lai TY, Yu HG, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015;99:289–96. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345796/.
  17. 17.
    Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110:1297–305. https://www.aaojournal.org/article/S0161-6420(03)00461-5/fulltext.
  18. 18.
    Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003;87:570–3. https://bjo.bmj.com/content/87/5/570.long
  19. 19.
    Leveziel N, Gaucher D, Baillif S, Benouaich X, Chartier C, Grenet T, et al. Understanding the determinants of myopic choroidal neovascularization and response to treatment. Eur J Ophthalmol. 2016;26:511–6. https://www.ncbi.nlm.nih.gov/pubmed/27515571.
  20. 20.
    Muakkassa NW, Chin AT, de Carlo T, Klein KA, Baumal CR, Witkin AJ, et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina. 2015;35:2252–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26457400.CrossRefGoogle Scholar
  21. 21.
    Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001;108:841–52 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11320011.CrossRefGoogle Scholar
  22. 22.
    Leveziel N, Caillaux V, Bastuji-Garin S, Zmuda M, Souied EH. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am. J. Ophthalmol. 2013:913–919.e1 Available from: http://linkinghub.elsevier.com/retrieve/pii/S000293941200832X.
  23. 23.
    Spaide RF. Choroidal neovascularization. In: Spaide R, Ohno-Matsui K, Yannuzzi L, editors. Pathologic myopia. New York: Springer; 2014.CrossRefGoogle Scholar
  24. 24.
    • Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, et al. Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology [Internet]. American Academy of Ophthalmology; 2017;124:1690–711. Available from:  https://doi.org/10.1016/j.ophtha.2017.04.028. The article review and assemble information about myopic choroidal neovascularization concepts and recently developed treatments.
  25. 25.
    Keane PA, Chang KT, Walsh AC. NIH public access. Reading. 2009;92:1081–5.Google Scholar
  26. 26.
    Guyer D, Yannuzzi L, Slakter J, Al E. Diagnostic indocyanine green angiography videoangiography. In: Ryan SJ, Schachat AP, eds. Retina. 3. St. Louis, MO: Mosby; 2001. p. 943–66.Google Scholar
  27. 27.
    Rush RB, Rush SW. Evaluation of idiopathic choroidal neovascularization with indocyanine green angiography in patients undergoing bevacizumab therapy. J. Ophthalmol. 2015;2015:642624 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26113990.Google Scholar
  28. 28.
    Lai TYY, Luk FOJ, Lee GKY, Lam DSC. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26:1004–11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22595908.CrossRefGoogle Scholar
  29. 29.
    Miyake M, Yamashiro K, Akagi-Kurashige Y, Kumagai K, Nakata I, Nakanishi H, et al. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology. 2014;121:225–33 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23953100.
  30. 30.
    Introini U, Casalino G, Querques G, Gimeno AT, Scotti F, Bandello F. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye [internet]. Nat Publ Group. 2012;26:976–82. Available from:.  https://doi.org/10.1038/eye.2012.75.Google Scholar
  31. 31.
    Lai TYY, Cheung CMG. Myopic choroidal neovascularization diagnosis and treatment. Retina. 2016;36:1614–21. https://www.ncbi.nlm.nih.gov/pubmed/27482641
  32. 32.
    Lumbroso B, Rispoli M, Savastano MC. Longitudinal optical coherence tomography-angiography study of type 2 naive choroidal neovascularization early response after treatment. Retina. 2015;35:2242–51. https://www.ncbi.nlm.nih.gov/pubmed/26457401.
  33. 33.
    Querques L, Giuffrè C, Corvi F, Zucchiatti I, Carnevali A, De Vitis LA, et al. Optical coherence tomography angiography of myopic choroidal neovascularisation. Br J Ophthalmol. 2017;101:609–15. https://www.ncbi.nlm.nih.gov/pubmed/27531357.
  34. 34.
    Bottoni F, Airaghi P, Perego E, Ortolina S, Carlevaro G, De Molfetta V. Surgical removal of idiopathic, myopic and age-related subfoveal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 1996;234(Suppl):S42–50 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8871149.CrossRefGoogle Scholar
  35. 35.
    Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch. Ophthalmol. (Chicago, Ill. 1960). 2000;118:344–50 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10721956.CrossRefGoogle Scholar
  36. 36.
    Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients. Br. J. Ophthalmol. 2001;85:1041–3 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11520751.CrossRefGoogle Scholar
  37. 37.
    Glacet-Bernard A, Simon P, Hamelin N, Coscas G, Soubrane G. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am. J. Ophthalmol. 2001;131:78–89 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11162982.CrossRefGoogle Scholar
  38. 38.
    Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv. Ophthalmol. 53:121–38 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18348878.
  39. 39.
    Fujikado T, Ohji M, Kusaka S, Hayashi A, Kamei M, Okada AA, et al. Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy. Am. J. Ophthalmol. 2001;131:101–10 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11162984.CrossRefGoogle Scholar
  40. 40.
    Yamada Y, Miyamura N, Suzuma K, Kitaoka T. Long-term follow-up of full macular translocation for choroidal neovascularization. Am. J. Ophthalmol. 2010;149:453–7.e1 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20035923.CrossRefGoogle Scholar
  41. 41.
    Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur. J. Ophthalmol. 12:117–22 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12022283.
  42. 42.
    Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195–214. https://www.ncbi.nlm.nih.gov/pubmed/11094244.
  43. 43.
    Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003;110:667–73 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12689884.CrossRefGoogle Scholar
  44. 44.
    Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol. 2003;87:173–6. https://bjo.bmj.com/content/87/2/173.long.
  45. 45.
    Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121:682–92. https://www.ncbi.nlm.nih.gov/pubmed/24326106.
  46. 46.
    Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye [internet]. Nat Publ Group. 2013;27:709–15. Available from:.  https://doi.org/10.1038/eye.2013.8.
  47. 47.
    Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the repair study. Ophthalmology. 2013;120:1944–6. https://www.aaojournal.org/article/S0161-6420(13)00501-0/fulltext.
  48. 48.
    Franqueira N, Cachulo ML, Pires I, Fonseca P, Marques I, Figueira J, et al. Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica. 2012;227:39–44 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22056757.CrossRefGoogle Scholar
  49. 49.
    Monés JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond). 2009;23:1275–80 quiz 1281. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19478826.CrossRefGoogle Scholar
  50. 50.
    Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010;30:407–12 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20094007.CrossRefGoogle Scholar
  51. 51.
    Lai TYY, Chan W-M, Liu DTL, Lam DSC. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009;29:750–6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19357555.CrossRefGoogle Scholar
  52. 52.
    Wu TT, Kung YH. Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization. Retina. 2017;37:2056–61. https://www.ncbi.nlm.nih.gov/pubmed/28590318.
  53. 53.
    Ceklic L, Munk MR, Wolf-Schnurrbusch U, Gekkieva M, Wolf S. Visual acuity outcomes of ranibizumab treatment in pathologic myopic eyes with macular retinoschisis and choroidal neovascularization. Retina. 2017;37:687–93. https://www.ncbi.nlm.nih.gov/pubmed/27533774.
  54. 54.
    Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik J-F, Vitti R, Li T, et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology. 2015;122:1220–7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25745875.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Ophthalmology St. Paul’s Eye UnitRoyal Liverpool University HospitalLiverpoolUK
  2. 2.Department of Ophthalmology, Bascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineMiamiUSA
  3. 3.Miami Veterans Administration Medical CenterMiamiUSA

Personalised recommendations